Softwr

Healthcare · head to head

Beckman Coulter DxONE vs Paige

Beckman Coulter DxONE logo

Beckman Coulter DxONE

Healthcare

Clinical laboratory middleware and informatics from a diagnostics instrument manufacturer

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Beckman Coulter DxONE the rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Beckman Coulter DxONE covers DxONE Command Central, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Beckman Coulter DxONE and Paige actually diverge.

Attributes where Beckman Coulter DxONE and Paige differ
AttributeBeckman Coulter DxONEPaige
PlatformsWeb, WindowsWeb, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Beckman Coulter DxONE

  • DxONE Command Central
  • DxONE Workflow Manager
  • REMISOL Advance
  • DxONE Inventory Manager
  • Autoverification rules
  • Quality control monitoring
  • LIS interfacing

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Beckman Coulter DxONE

  • A hospital laboratory standardising on Beckman DxC and DxI analysers that wants autoverification to release the majority of routine chemistry without technologist reviewnot Paige
  • A low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules enginenot Paige
  • A multi site laboratory network that needs identical autoverification rules applied consistently across every site, which REMISOL Advance is built fornot Paige
  • A laboratory whose LIS cannot express delta checks or repeat rules and needs that logic to live in middleware insteadnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Beckman Coulter DxONE
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Beckman Coulter DxONE
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Beckman Coulter DxONE
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Beckman Coulter DxONE

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Beckman Coulter DxONE

  • The rules and quality control workflows are tuned to Beckman analysers, so laboratories with a mixed Roche, Abbott and Siemens fleet get materially less coverage and typically buy vendor neutral middleware such as Data Innovations Instrument Manager instead.
  • Pricing is bundled into analyser and reagent contracts rather than itemised, so a laboratory cannot compare the informatics cost against a standalone middleware quote and often does not know what it is paying for the software.
  • Because the software is tied to a reagent rental term, the real cost of switching middleware is the remaining years of the reagent commitment, not a software renewal, which locks the laboratory in far longer than a software contract would.
  • DxONE Workflow Manager and REMISOL Advance are different products with different rule engines rather than one product at two sizes, so a laboratory that grows out of Workflow Manager faces a migration and rule rewrite, not an upgrade.
  • Interface builds to the hospital LIS are professional services work quoted per interface, and laboratories consistently underestimate this line, particularly where the LIS is an older Sunquest or SCC installation.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Beckman Coulter DxONE

On request
  • DxONE$undefined/year
    • Quoted as part of an analyser or reagent contract, not as standalone software
    • Priced against instrument fleet size and test volume
    • Multi year reagent rental agreements are the usual commercial vehicle

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Beckman Coulter DxONE if

  • You need dxone command central.
  • You work on Web, Windows.
  • You also want dxone workflow manager.
Beckman Coulter DxONE review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Beckman Coulter DxONE or Paige better?
Neither clearly leads. Beckman Coulter DxONE starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Beckman Coulter DxONE or Paige?
Beckman Coulter DxONE starts at On request and Paige at On request.
Does Beckman Coulter DxONE or Paige run on more platforms?
Beckman Coulter DxONE runs on Web, Windows. Paige runs on Web, Cloud, On-premise.
What is Beckman Coulter DxONE best used for?
Beckman Coulter DxONE is most often used for a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review, a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine, a multi site laboratory network that needs identical autoverification rules applied consistently across every site, which remisol advance is built for, a laboratory whose lis cannot express delta checks or repeat rules and needs that logic to live in middleware instead. Of those, a hospital laboratory standardising on beckman dxc and dxi analysers that wants autoverification to release the majority of routine chemistry without technologist review and a low volume rural laboratory that cannot justify on premises middleware servers and needs a cloud hosted rules engine are not what Paige is typically brought in for.
What can Beckman Coulter DxONE do that Paige cannot?
Beckman Coulter DxONE covers DxONE Command Central, DxONE Workflow Manager, REMISOL Advance, DxONE Inventory Manager. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Beckman Coulter DxONE: Can I buy DxONE without buying Beckman analysers?

Not realistically. It is quoted as part of an instrument or reagent agreement and its value is in the depth of integration with Beckman platforms. A laboratory with other analysers should look at vendor neutral middleware.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Beckman Coulter DxONE: Is DxONE the same as REMISOL Advance?

No. REMISOL Advance is the on premises middleware for higher volume and multi site laboratories. DxONE Workflow Manager is a separate cloud product aimed at low volume laboratories. They are not the same rule engine.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Beckman Coulter DxONE: Does Beckman publish pricing?

No. Everything is quoted, and the software cost is usually folded into a cost per reportable result on a reagent contract rather than shown as a licence fee.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Beckman Coulter DxONE: Is DxONE a regulated medical device?

The middleware components carry regulatory registrations that vary by product and region. Autoverification of diagnostic results is a regulated function, so confirm the specific clearance for the module and country before deployment.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Beckman Coulter DxONE

More on Paige

Keep looking

Other head to heads